Innovus Pharma Announces Receipt of Notification to Commercialize Sensum+® in the European Union

Sensum+® and Zestra® Now
Ready to be Commercialized in Europe

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty
pharmaceutical company engaged in the commercialization, licensing and
development of safe and effective non-prescription medicine and consumer
care products to improve men’s and women’s health and vitality and
respiratory diseases, announced today that it received the CPNP
notification number required to commercialize Sensum+® in all
28 member countries of the European Union.

“We are pleased to continue to expand the commercial opportunity of our
products into the European Union, the largest market after the United
States,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Now that we have
received the CPNP notification numbers for Sensum+® and for
Zestra®, which we announced last week, Innovus has two
products ready to be commercialized in the European Union, and
therefore, expanding our ability to enter into additional commercial
partnerships.”

Innovus Pharma currently partners Sensum+ internationally with Orimed in
Canada, Tramorgen Limited in the United Kingdom, Elis Pharma in Turkey
and certain select markets, BroadMed SAL for Lebanon, Ovation for
Morocco, Khandelwal Laboratories, PVT, Inc. for India, Nepal, Bhutan,
Sri Lanka and Bangladesh, Tabuk Pharma for select Middle Eastern
countries, and Oz Biogenics for Myanmar and Vietnam.

Sensum+® is currently approved to be marketed and sold in 31
countries worldwide including the United States, Europe, India and
Morocco. In addition to the United States, the largest market for Sensum+®,
Innovus Pharma currently generates Sensum+® revenues from the
following markets: the United Kingdom and Morocco.

About Sensum+® and Reduced Penile Sensitivity

Sensum+® is a non-medicated cream which moisturizes the head
and shaft of the penis for enhanced feelings of sensation and greater
sexual satisfaction. It is a patent-pending blend of essential oils and
ingredients generally recognized as safe that recently commenced
marketing in the U.S. The safety and efficacy of Sensum+® was
evaluated in two post-marketing clinical survey studies in circumcised
and non-circumcised men. A total of 382 men used Sensum+®
twice daily for 14 consecutive days followed by once daily for eight
weeks and as needed thereafter. Study participants reported a ~50%
increase in penile sensitivity with the use of Sensum+®. For
more information, visit www.sensumplus.com
or www.sensumplus.co.uk
for UK customers.

Reduced Penile Sensitivity (“RPS”) results form a gradual loss of penile
sensitivity over time. RPS is observed in diabetic patients, patients
suffering from multiple sclerosis, 20% of patients undergoing hernia
surgery and circumcised men.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (“OTC”) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists and therapists, and
(c) directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(“ANDA”) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the sale of Sensum+® in Europe,
the sale of the Company’s other products, projected online subscribers,
estimated market for its products, and statements about achieving its
other development, growth, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company’s most recent filing
on Form S-1, annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC’s website or without charge from the
Company.

Contacts

Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com